Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
35 participants
INTERVENTIONAL
2017-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme
NCT04588454
[11C]Acetate PET in Patients With Glioma
NCT02986815
PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor
NCT02071017
68Ga-NOTA-RM26 PET/CT in Glioma Patients
NCT06412952
68Ga-citrate PET/MR Imaging for Glioma
NCT03335280
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
uPAR PET/MRI
One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
One injection of 68Ga-NOTA-AE105
One injection of 68Ga-NOTA-AE105
PET/MRI
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One injection of 68Ga-NOTA-AE105
One injection of 68Ga-NOTA-AE105
PET/MRI
Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participants must be capable of understanding and giving full informed written consent
* age above 18 years
Exclusion Criteria
* Lactation/breast feeding
* Age above 85 years old
* Weight above 140 kg
* Known allergy towards 68Ga-NOTA-AE105
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dorthe Skovgaard
Principal investigator, MD, Phd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dorthe Skovgaard, Md, PhD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Azam A, Kurbegovic S, Carlsen EA, Andersen TL, Larsen VA, Law I, Skjoth-Rasmussen J, Kjaer A. Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy. EJNMMI Res. 2024 Oct 29;14(1):100. doi: 10.1186/s13550-024-01164-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-002417-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AK2016-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.